Akero Therapeutics Inc (AKRO) Stock Price, Quote & News

Company Profile

Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 487 6488

Website: akerotx.com

Address:

601 Gateway Boulevard, Suite 350, South San Francisco, United States

Wallst45 Jul. 30 at 11:33 AM

$MDGL SYH2086 is an Orforglipron derivative. Perfect move by Madrigal. Combination therapy works wonders. $LLY Lilly’s Orforglipron, oral GLP-1 is a proven drug which is in approval phase There is a reason why $AKRO Akero stock has been coming down significantly lately

0 · Reply

Wallst45 Jul. 29 at 6:02 PM

$AKRO 47 yay. Still holding till 40

0 · Reply

BioRich Jul. 27 at 6:30 PM

$ALT Folks, ALT's Alcohol-associated Liver Disease (ALD) trial is a sexy headline of hope that lacks true value and wastes YOUR (shareholder) money. Let me explain: 1) This is not a special or unique trial. It's essentially a 2.4mg compliment to the MASH P2b trial, which ALT plans to include in P3 anyway IF they get the greenlight. 2) Trial completion data is August 31st...2027!!! More than 2 years until this 100-patient trial is expected to be completed. Simple napkin math shows that they don't plan to be enrolled for over a year from now! 3) Primary endpoint is Relative change (%) in VCTE at 24W. That's it. 4) Secondary endpoints are the single primary endpoint at 48 weeks and absolute change in ELF score at 24W and 48W. That's it folks. That's the ALD hype, simplified. Link to Trial and pertinent MASH P2b results: https://clinicaltrials.gov/study/NCT07009860?cond=ALD&limit=10&sort=@relevance&term=ALT-801&rank=1&tab=table $XBI $VKTX $MDGL $AKRO

3 · Reply

Biotech_Beast Jul. 24 at 3:26 PM

$ALT has recovered a bit since MASH data caused the stock to drop in late June. I took a look at the name which could still have more data around December. $AKRO $ETNB https://seekingalpha.com/article/4803797-altimmune-stock-potential-tough-road-ahead-amid-fierce-competition-rating-downgrade

2 · Reply

Ohzipit Jul. 24 at 1:10 PM

$AKRO $ALT $MDGL $VKTX best is class $4.12 a share and no meaningful cash to move forward?

1 · Reply

Theverypatientone Jul. 24 at 12:07 PM

$ALT BIC vs $AKRO, $MDGL, $VKTX you should do your DD. Pemvi is a different platform and completely different from the rest. No BP will seek a partmership or BO with platforms that are inderior and are either Obesiety or Nash or cirhosis or CV improments. They are seeking a platform that effects all with superior safety profile. Only Pemvi does that.

3 · Reply

Okadarlan Jul. 23 at 4:49 PM

$AKRO Sloppy back to 28.

0 · Reply

BioRich Jul. 23 at 2:13 PM

$ALT MASH Resolution vs. $AKRO MASH Resolution (at 24W) ALT: 1.8mg effective improvement over placebo: 33% AKRO: 50 mg effective improvement over placebo: 61% Still thinking $ALT is a good buy? $XBI

5 · Reply

BioRich Jul. 22 at 8:10 PM

$ALT Friendly reminder: 1) Obesity is dead 2) MASH is crippled 3) ALD and AUD are useless 4) $ALT has been subject of lawsuits and SEC complaints for misleading shareholders. 5) Huge dilution has occurred regularly. 6) Company radio silent following fibrosis improvement fail, leaving SH's to fend for and defend themselves. 7) No notable data for at least a year and a half. 8) Severely behind competitors that have better products. 9) Shorts aren't covering and haven't, even going into data. No one respects this snakeoil outfit, and for good reason. 10) Many bagholders on this board trying to make this seem like a good investment while likely know it's not so they can cover their losses. Invest wisely folks. For more perspective and suggestions, follow/subscribe. Would love to hear yours too. That's how we learn. Let's make some money. Cheers! $XBI $VKTX $MGDL $AKRO

4 · Reply

Quantumup Jul. 22 at 12:10 PM

Citizens reiterated $MDGL Mkt OP/$470 after its 2Q25 survey showed a 46% prescription rate for Rezdiffra (up from 42% in its 1Q survey)" $IVA $AKRO $ALGS $VKTX ETNB SGMT LLY #MASH Citizens in its note to investors said, "Our 2Q25 survey shows a 46% prescription rate for Rezdiffra (up from 42% in our 1Q survey), with ~60% of patients on paid drug and consistent high persistence; we reiterate our Market Outperform rating and $470 risk-adjusted, DCF-derived price target on Madrigal Pharmaceuticals. Most metrics in our 2Q25 physician survey improved from 1Q, which is a good sign coming out of the typical 1Q reimbursement dynamics. Citizens additionally said:

0 · Reply

Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation

Jun 5, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect

Jun 3, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out

Jun 3, 2025, 7:00 AM EDT - 2 months ago

Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 1, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Shareholders to Learn More About the Investigation

May 29, 2025, 10:05 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation

May 28, 2025, 7:00 AM EDT - 2 months ago

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

May 27, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation

May 25, 2025, 10:00 AM EDT - 2 months ago

Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 22, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Connect

May 21, 2025, 3:25 PM EDT - 2 months ago

Akero: FGF21 Advancement For MASH Targeting Presses On With Key Developments

May 18, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out

May 15, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect

May 13, 2025, 10:00 AM EDT - 2 months ago

Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 12, 2025, 7:00 AM EDT - 2 months ago

Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 11, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Stockholders to Learn More About the Investigation

May 10, 2025, 10:00 AM EDT - 2 months ago

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

May 9, 2025, 7:41 AM EDT - 2 months ago

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025

May 9, 2025, 7:11 AM EDT - 2 months ago

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

May 8, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Investors to Inquire about Securities Investigation

May 7, 2025, 4:05 PM EDT - 3 months ago

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference

Apr 30, 2025, 7:00 AM EDT - 3 months ago

Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025

Apr 29, 2025, 10:00 AM EDT - 3 months ago

Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 6, 2025, 1:47 PM EDT - 4 months ago

Akero Therapeutics: Cirrhosis Reversal Data Derisks The Stock

Feb 28, 2025, 7:00 AM EST - 5 months ago

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 4, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Reach Out

Jan 30, 2025, 4:05 PM EST - 6 months ago

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 28, 2025, 9:30 PM EST - 6 months ago

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

Jan 28, 2025, 2:38 PM EST - 6 months ago

Akero: Reversal Of Cirrhosis With EFX Is A 'First' In F4 MASH Patients

Jan 27, 2025, 4:01 PM EST - 6 months ago

Akero Therapeutics Announces Proposed Public Offering of Common Stock

Jan 27, 2025, 12:10 PM EST - 6 months ago

Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results

Jan 27, 2025, 11:30 AM EST - 6 months ago

Why did Akero (AKRO) stock soar 110% on Monday?

Jan 27, 2025, 9:01 AM EST - 6 months ago

Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why

Jan 27, 2025, 6:52 AM EST - 6 months ago

Akero shares double after preliminary results from mid-stage trial for liver disease drug

Jan 27, 2025, 6:30 AM EST - 6 months ago

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

Jan 24, 2025, 4:05 PM EST - 6 months ago

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Jan 24, 2025, 11:01 AM EST - 6 months ago

Kuehn Law Encourages Investors of Akero Therapeutics, Inc. to Contact Law Firm

Nov 15, 2024, 11:00 AM EST - 9 months ago

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

Nov 13, 2024, 4:05 PM EST - 9 months ago

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 8, 2024, 7:00 AM EST - 9 months ago

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 21, 2024, 7:00 AM EDT - 10 months ago

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024

Sep 30, 2024, 7:00 AM EDT - 10 months ago

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference

Sep 20, 2024, 3:37 PM EDT - 11 months ago

Akero Therapeutics: Good Candidate For The MASH Basket

Sep 9, 2024, 7:00 AM EDT - 11 months ago

Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH

Aug 28, 2024, 4:05 PM EDT - 1 year ago

Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 9, 2024, 7:00 AM EDT - 1 year ago

Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 28, 2024, 10:40 AM EDT - 1 year ago

Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm

Jun 21, 2024, 10:40 AM EDT - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics

Wallst45 Jul. 30 at 11:33 AM

0 · Reply

Wallst45 Jul. 29 at 6:02 PM

$AKRO 47 yay. Still holding till 40

0 · Reply

BioRich Jul. 27 at 6:30 PM

3 · Reply

Biotech_Beast Jul. 24 at 3:26 PM

2 · Reply

Ohzipit Jul. 24 at 1:10 PM

$AKRO $ALT $MDGL $VKTX best is class $4.12 a share and no meaningful cash to move forward?

1 · Reply

Theverypatientone Jul. 24 at 12:07 PM

3 · Reply

Okadarlan Jul. 23 at 4:49 PM

$AKRO Sloppy back to 28.

0 · Reply

BioRich Jul. 23 at 2:13 PM

$ALT MASH Resolution vs. $AKRO MASH Resolution (at 24W) ALT: 1.8mg effective improvement over placebo: 33% AKRO: 50 mg effective improvement over placebo: 61% Still thinking $ALT is a good buy? $XBI

5 · Reply

BioRich Jul. 22 at 8:10 PM

4 · Reply

Quantumup Jul. 22 at 12:10 PM

0 · Reply

BiotechBonesaw Jul. 21 at 11:36 PM

$GPCR have any $ALT $AKRO $MDGL or $VKTX checked this out as an earlier stage oral GLP-1 alternative? @squiggleburp & @Hoppanin - any interest?

2 · Reply

Damnthisappilosthistory Jul. 21 at 5:00 AM

$ALT curious if anyone has some view on the extremely large valuation gap between $ALT and $AKRO, even pre-P2 results?

2 · Reply

Damnthisappilosthistory Jul. 20 at 6:37 AM

$ALT curious if anyone has some view on the extremely large valuation gap between $ALT and $AKRO, even pre-P2 results?

0 · Reply

Damnthisappilosthistory Jul. 19 at 3:55 PM

$ALT did $AKRO get a partner yet?

1 · Reply

Kevinwilson9 Jul. 19 at 4:37 AM

$AKRO showing a strong base. Might be ready for the next leg up.

0 · Reply

All_just_a_game Jul. 16 at 8:43 PM

$AKRO $ALT $MDGL $VKTX lmfao 😂 The bitch in class ALT drug can’t get a partner.

1 · Reply

Thepatientone Jul. 16 at 7:06 PM

$ALT BIC vs $AKRO, $MDGL, $VKTX - The agonists are the platform of the future..

1 · Reply

Thepatientone Jul. 16 at 6:54 PM

$ALT BIC vs $AKRO, $MDGL, $VKTX

2 · Reply

INEEDMONNEY Jul. 16 at 6:54 PM

$AKRO $ALT $MDGL $VKTX can someone help me out with this? Is a lower or high number for wight loss best? i know pemvi is for mash but if were talking about weight loss isnt retatrutide BIC? Im long ALT im just confused how this graph is saying its BIC

4 · Reply

Thepatientone Jul. 16 at 6:49 PM

$ALT BIC vs $AKRO, $MDGL, $VKTX

1 · Reply

GPTInsights Jul. 16 at 6:49 PM

$VKTX $ALT $AKRO $MDGL No you just spam arbitrary old information and claim best in class but you don't know what you are talking about. There is a reason ALT has been trending down for a decade and got cut in half on results and GS gave it a $1 PT.

2 · Reply

Thepatientone Jul. 16 at 6:46 PM

$ALT BIC vs $AKRO, $MDGL, $VKTX

0 · Reply

Market Cap	3.79B
Revenue (ttm)	0.00
Net Income (ttm)	-252.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.03

Volume	1,160,400
Avg Vol	1,601,234
Day's Range	N/A - N/A
Shares Out	79.72M
Stochastic %K	10%
Beta	-0.15
Analysts	Strong Sell
Price Target	$76.64